


## Edoxaban hydrochloride

Cat. No.:	HY-10264C
CAS No.:	480448-29-1
Molecular Formula:	C <sub>24</sub> H <sub>31</sub> Cl <sub>2</sub> N <sub>7</sub> O <sub>4</sub> S
Molecular Weight:	584.52
Target:	Factor Xa; Thrombin
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



H-Cl

### BIOLOGICAL ACTIVITY

<b>Description</b>	Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K <sub>i</sub> values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research <sup>[1]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 2.90 μM (platelet aggregation), K <sub>i</sub> : 0.561 nM (free human FXa), 2.98 nM (prothrombinase), 0.715 nM (cynomolgus monkey FXa), 0.457 nM (rabbit FXa) <sup>[1]</sup>								
<b>In Vitro</b>	<p>Edoxaban hydrochloride (1, 1 and 5 minutes respectively) prolongs PT,TT and APTT of human plasma in a concentration-dependent manner<sup>[1]</sup>.</p> <p>Edoxaban hydrochloride inhibits thrombin-induced platelet aggregation, with an IC<sub>50</sub> of 2.90 μM<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human, rat, cynomolgus monkey and rabbit plasma; Human platelet</td> </tr> <tr> <td>Concentration:</td> <td></td> </tr> <tr> <td>Incubation Time:</td> <td>1 and 5 minutes</td> </tr> <tr> <td>Result:</td> <td>Antithrombin.</td> </tr> </table>	Cell Line:	Human, rat, cynomolgus monkey and rabbit plasma; Human platelet	Concentration:		Incubation Time:	1 and 5 minutes	Result:	Antithrombin.
Cell Line:	Human, rat, cynomolgus monkey and rabbit plasma; Human platelet								
Concentration:									
Incubation Time:	1 and 5 minutes								
Result:	Antithrombin.								
<b>In Vivo</b>	<p>Edoxaban hydrochloride (0.5, 2.5 and 12.5 mg/kg; p.o.; once) significantly and dose-dependently reduces the thrombus formation and prolongs PT<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Slc: Wistar rats (210-240 g); Male New Zealand White rabbits(2.5-3.5 kg) (Both are venous stasis thrombosis model)<sup>[1]</sup>.</td> </tr> <tr> <td>Dosage:</td> <td>0.5, 2.5 and 12.5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration; once</td> </tr> </table>	Animal Model:	Male Slc: Wistar rats (210-240 g); Male New Zealand White rabbits(2.5-3.5 kg) (Both are venous stasis thrombosis model) <sup>[1]</sup> .	Dosage:	0.5, 2.5 and 12.5 mg/kg	Administration:	Oral administration; once		
Animal Model:	Male Slc: Wistar rats (210-240 g); Male New Zealand White rabbits(2.5-3.5 kg) (Both are venous stasis thrombosis model) <sup>[1]</sup> .								
Dosage:	0.5, 2.5 and 12.5 mg/kg								
Administration:	Oral administration; once								

---

Result:

Inhibited exogenous FXa activity.  
Antithrombotic.

---

## CUSTOMER VALIDATION

- Thromb Res. 2021 Jan;197:141-143.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Furugohri T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep;6(9):1542-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA